Literature DB >> 18846114

International progress in cancer gene therapy.

B A Guinn1, R Mulherkar.   

Abstract

We overview the current status and most recent developments in the field of cancer gene therapy from an international viewpoint. We have largely based our review on presentations from the eighth annual meeting of the International Society for Cell and Gene Therapy of Cancer held in Mumbai, India (www.iscgt.com and www.iscgtindia.com). This has afforded us with the opportunity to describe the most recently published and unpublished data in the field of cancer gene therapy, gaining an insight into the priorities in this field today. In doing so, we hope to have provided a state of the art review of cancer gene therapy, with the help of some of the best-known researchers in the field. In addition, due to the location of the meeting, we had a unique opportunity to listen to some of the seminal cancer gene therapy work being performed in India at this time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18846114     DOI: 10.1038/cgt.2008.66

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  9 in total

1.  Lentivirus-delivered Krüppel-like factor 8 small interfering RNA inhibits gastric cancer cell growth in vitro and in vivo.

Authors:  Lili Liu; Na Liu; Min Xu; Yi Liu; Jie Min; Hailin Pang; Ning Zhang; Hongbo Zhang; Helong Zhang
Journal:  Tumour Biol       Date:  2011-11-15

2.  The attitude of oncology physicians and nurses to the acceptance of new drugs for gene therapy.

Authors:  Zi-ming Liu; Chang Liu; Jun-ying Li; Chun-hua Yu; Yu Jiang
Journal:  J Cancer Educ       Date:  2011-06       Impact factor: 2.037

3.  Physicochemical and biological properties of self-assembled antisense/poly(amidoamine) dendrimer nanoparticles: the effect of dendrimer generation and charge ratio.

Authors:  Alireza Nomani; Ismaeil Haririan; Ramin Rahimnia; Shamileh Fouladdel; Tarane Gazori; Rassoul Dinarvand; Yadollah Omidi; Ebrahim Azizi
Journal:  Int J Nanomedicine       Date:  2010-05-13

4.  RNAi-mediated HOXD3 knockdown inhibits growth in human RKO cells.

Authors:  Fangjun Chen; Guoping Sun; Jun Peng
Journal:  Oncol Rep       Date:  2016-08-02       Impact factor: 3.906

5.  Shape and Boundary Similarity Features for Accurate HCC Image Recognition.

Authors:  Xiaoyu Duan; Huiyan Jiang; Siqi Li
Journal:  Biomed Res Int       Date:  2017-11-07       Impact factor: 3.411

6.  Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy.

Authors:  Yi Zheng; Hongbo Chen; Xiaowei Zeng; Zhigang Liu; Xiaojun Xiao; Yongqiang Zhu; Dayong Gu; Lin Mei
Journal:  Nanoscale Res Lett       Date:  2013-04-09       Impact factor: 4.703

7.  Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer.

Authors:  Bo Qiu; Minghui Ji; Xiaosong Song; Yongqiang Zhu; Zhongyuan Wang; Xudong Zhang; Shu Wu; Hongbo Chen; Lin Mei; Yi Zheng
Journal:  Nanoscale Res Lett       Date:  2012-12-06       Impact factor: 4.703

8.  RNAi-mediated RPL34 knockdown suppresses the growth of human gastric cancer cells.

Authors:  Hui Liu; Shaohua Liang; Xi Yang; Zhaoning Ji; Wenying Zhao; Xiaobing Ye; Jing Rui
Journal:  Oncol Rep       Date:  2015-08-21       Impact factor: 3.906

9.  RNAi‑mediated downregulation of asparaginase‑like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa.

Authors:  Xiao-Feng Lv; Han-Qing Hong; Ling Liu; Shi-Hong Cui; Chen-Chen Ren; Hong-Yu Li; Xiao-An Zhang; Lin-Dong Zhang; Tian-Xiang Wei; Jin-Jin Liu; Wen-Ying Xing; Han Fu; Shu-Jun Yan
Journal:  Mol Med Rep       Date:  2018-05-14       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.